Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

Isomorphic Labs is the secretive AI life science startup spun out of Google DeepMind with the goal of solving all disease ...

What if it’s not "just a game"? In AI, games are more than just fun—they can reconceive what’s possible. Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, knows this firsthand.

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Isomorphic Labs was founded to apply artificial intelligence to drug discovery. The company is led by AI researcher Sir Demis Hassabis.